Welcome to our dedicated page for Shuttle Pharmaceuticals Holdings news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on Shuttle Pharmaceuticals Holdings stock.
Shuttle Pharmaceuticals Holdings, Inc. develops cancer-therapy programs and drug-development technologies, with a focus on radiotherapy-related treatments and the Molecule.ai platform for molecular discovery and early-stage drug development. Its updates commonly address pipeline and platform development, including Ropidoxuridine, HDAC inhibitors, PSMA-B, PC-Rad Test and AI models for evaluating biological targets and therapeutic candidates.
Company news also includes financing activity, securities offerings, material agreements, shareholder-voting matters, governance updates and operating or financial results. The completed acquisition of Molecule.ai added an artificial-intelligence software asset to Shuttle Pharma's drug-discovery and predictive-analytics capabilities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced a research agreement with Georgetown University to evaluate its lead HDAC6 inhibitor candidate, SP-2-225. The collaboration will focus on the anti-tumor effects of SP-2-225 in combination with radiation therapy (RT) using a breast cancer model. The research aims to support IND-enabling studies in 2023 with plans for a Phase I clinical trial in 2024. SHPH's pipeline includes Ropidoxuridine, aimed at enhancing cancer cell sensitivity to RT, which is progressing towards Phase II testing in brain cancer patients. This partnership underscores SHPH's commitment to improving cancer treatment outcomes.